Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meral Beksac

Showing results (51-60 of 185) with videos related to

Pageof 19
Sort By:
European Journal of Haematology|November 18, 2014
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocationChristof Scheid, Donna Reece, Meral Beksac, et al.
Acta Haematologica|April 1, 2015
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groupsMeral Beksac, Anders Waage, Sara Bringhen, et al.
Blood Cancer Journal|March 22, 2022
Extramedullary disease in multiple myeloma: a systematic literature reviewJoan Bladé, Meral Beksac, Jo Caers, et al.
Fetal and Pediatric Pathology|August 23, 2019
Fetal Cell Microchimerism; Normal and Immunocompromised Gestations in MiceM Sinan Beksac, Erdem Fadiloglu, Ayse Nur Cakar, et al.
Balkan Medical Journal|March 24, 2023
Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single CenterGuldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, et al.
Cell Death & Disease|February 25, 2021
Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myelomaRenjie Dou, Jinjun Qian, Wei Wu, et al.
Immunogenetics|September 18, 2021
A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severityMeral Beksac, Hasan Yalim Akin, Emine Begum Gencer-Oncul, et al.
Leukemia Research|September 15, 2022
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMAMeral Beksac, Ivan Spicka, Roman Hajek, et al.
Journal of Hematology & Oncology|April 2, 2021
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNAFengjie Jiang, Xiaozhu Tang, Chao Tang, et al.
Expert Review of Anticancer Therapy|June 9, 2015
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Jacob P Laubach, Sagar Lonial, et al.
Pageof 19

Showing results (51-60 of 185) with videos related to

Sort By:
Pageof 19
European Journal of Haematology|November 18, 2014
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocationChristof Scheid, Donna Reece, Meral Beksac, et al.
Acta Haematologica|April 1, 2015
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groupsMeral Beksac, Anders Waage, Sara Bringhen, et al.
Blood Cancer Journal|March 22, 2022
Extramedullary disease in multiple myeloma: a systematic literature reviewJoan Bladé, Meral Beksac, Jo Caers, et al.
Fetal and Pediatric Pathology|August 23, 2019
Fetal Cell Microchimerism; Normal and Immunocompromised Gestations in MiceM Sinan Beksac, Erdem Fadiloglu, Ayse Nur Cakar, et al.
Balkan Medical Journal|March 24, 2023
Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single CenterGuldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, et al.
Cell Death & Disease|February 25, 2021
Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myelomaRenjie Dou, Jinjun Qian, Wei Wu, et al.
Immunogenetics|September 18, 2021
A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severityMeral Beksac, Hasan Yalim Akin, Emine Begum Gencer-Oncul, et al.
Leukemia Research|September 15, 2022
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMAMeral Beksac, Ivan Spicka, Roman Hajek, et al.
Journal of Hematology & Oncology|April 2, 2021
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNAFengjie Jiang, Xiaozhu Tang, Chao Tang, et al.
Expert Review of Anticancer Therapy|June 9, 2015
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Jacob P Laubach, Sagar Lonial, et al.
Pageof 19